早中期微卫星高度不稳定及稳定型结直肠癌的免疫治疗进展  

Advances in immunotherapy of early-middle stage colorectal cancer withmicrosatellite instability-high and stability

作　　者：郭梦雅 彭炜惟 方瑛[2] 沈波[2] 周国仁[1] GUO Mengya;PENG Weiwei;FANG Ying;SHEN Bo;ZHOU Guoren(Department of Oncology,Affiliated Cancer Hospital of Nanjing Medical University,Nanjing,Jiangsu 210009,China;不详)

机构地区：[1]南京医科大学附属肿瘤医院肿瘤科,江苏南京210009 [2]江苏省肿瘤医院江苏省肿瘤防治研究所肿瘤科,江苏南京210009

出　　处：《中国临床研究》2023年第12期1886-1889,共4页Chinese Journal of Clinical Research

基　　金：国家自然科学基金资助项目(82273162)。

摘　　要：免疫抑制剂改变了晚期结直肠癌患者的治疗格局,并彰显出了巨大的生存收益,目前指南获批的免疫药物已经在临床上广泛使用,但早中期结直肠癌患者主要治疗方式为手术切除、放疗、化疗、抗血管生成等综合治疗,免疫抑制剂在这些患者中的治疗地位尚未明确。本文就早中期微卫星不稳定及稳定型结直肠癌免疫治疗进展进行综述,总结了现有以及正在探索的免疫新辅助治疗或免疫联合疗法等模式,以期免疫治疗能为早中期结直肠癌患者提供更多的选择。Immunosuppressive drugs have changed the treatment pattern of patients with advanced colorectal cancer and demonstrated huge survival benefits.Currently,immune drugs approved by the guidelines have been widely used clinically,but the main treatment methods for patients with early and middle colorectal cancer are surgical resection,radiotherapy,chemotherapy,anti-angiogenesis and other comprehensive treatments.The therapeutic status of immunosuppressants in these patients is not yet clear.In this paper,immunotherapy for early-stage and mid-stage microsatellite instability and stability colorectal cancer is reviewed,and the existing and ongoing immunoneoadjuvant therapy or immunocombination therapy models are summarized,hoping that immunotherapy can provide more choices for patients with early-stage and mid-stage colorectal cancer.

关 键 词：微卫星不稳定 微卫星稳定 结直肠癌 早中期 免疫治疗 阿替利珠单抗 信迪利单抗 纳武利尤单抗 卡瑞利珠单抗 贝代珠单抗 特瑞普利单抗 

分 类 号：R735.3[医药卫生—肿瘤]